Mirum Pharmaceuticals, Inc. MIRM
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) is a rare genetic drug developer. Its lead program, zilurgisertib (Atebrioz), is in Phase 3 for fibrodysplasia ossificans progressiva (FOP). Its next catalyst on record is brelovitug: AZURE-4 Phase 3 topline results (Q4 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: brelovitug — AZURE-4 Phase 3 topline results (Q4 2026). 8 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| zilurgisertib (Atebrioz) | FOP | small molecule | Approved |
| maralixibat (Livmarli) | cholestatic pruritus in ALGS and PFIC | small molecule | Approved |
| cholic acid (Cholbam) | bile acid synthesis disorders and peroxisomal disorders | small molecule | Approved |
| chenodiol (Ctexli) | cerebrotendinous xanthomatosis (CTX) | small molecule | Approved |
| brelovitug (BJT-778) | chronic hepatitis D virus (HDV) infection | antibody | Phase 3 |
| volixibat | cholestatic pruritus in PSC and PBC | small molecule | Phase 3 |
| MRM-3379 | Fragile-X Syndrome (FXS) | small molecule | Phase 2 |
Recent results and decisions
- Nov 3, 2026approval Mirum received U.S. FDA approval of ATEBRIOZ (zilurgisertib) to reduce the volume of total new heterotopic ossification in adult and pediatric patients aged 12 years and older with FOP.
Received U.S. FDA approval of and launched ATEBRIOZ® (zilurgisertib) to reduce the volume of total new heterotopic ossification (HO) in adult and pediatric patients aged 12 years and older with fibrodysplasia ossificans progressiva (FOP).
Filing - Nov 3, 2026positive Mirum reported positive results from Cohort 2 of the PROGRESS study of ATEBRIOZ in pediatric patients aged 6 to <12 years with FOP.
Reported positive results from Cohort 2 of the PROGRESS study of ATEBRIOZ (zilurgisertib) in pediatric patients aged 6 to <12 years with FOP.
Filing - Nov 3, 2026met LIVMARLI EXPAND Phase 3 study in additional rare cholestatic conditions met the primary endpoint and achieved statistical significance across all prespecified secondary endpoints.
Reported LIVMARLI (maralixibat) EXPAND Phase 3 study in additional rare cholestatic conditions, including biliary atresia, met the primary endpoint and achieved statistical significance across all prespecified secondary endpoints.
Filing
9 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 rare genetic companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.